Pharmaron posts strong revenue growth, profit falls amid strategic expansions

Pharmaron Beijing Co., Ltd. reported an aggregate revenue of RMB6,441.0 million for the first six months of 2025, an increase of 14.9% compared to the same period in 2024. Gross profit also saw a rise of 17.5% to RMB2,172.2 million. However, profit attributable to owners of the parent decreased significantly by 37.0% to RMB701.4 million, primarily due to the absence of investment income from a prior year’s equity disposal. Despite this, non-IFRSs adjusted net profit attributable to owners of the parent increased by 9.5% to RMB755.7 million.

Net cash flows generated from operating activities improved by 28.1% to RMB1,408.3 million. The company continued its global expansion, with overseas subsidiaries contributing RMB802.2 million to revenue, up 8.9% year-on-year. Pharmaron also made strategic moves, including the acquisition of a controlling stake in Aistarfish Technology in February 2025 to enhance clinical data and AI capabilities, and committed RMB100 million to an equity investment fund. The board resolved not to declare any interim dividend for the period.